X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/pantherxrare-selected-by-edenbridge-pharmaceuticals-as-specialty-pharmacy-for-yargesa-miglustat-100-mg-capsules-302104863.html
https://www.globenewswire.com//news-release/2024/02/08/2825867/15991/en/Amicus-Therapeutics-Receives-the-2024-New-Treatment-Award-for-Pombiliti-cipaglucosidase-alfa-atga-Opfolda-miglustat-at-the-20th-Annual-WORLDSymposium.html
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-amicus-therapeutics-muscle-disorder-treatment-2023-09-28/
https://www.benzinga.com/pressreleases/23/08/g33854613/amicus-therapeutics-announces-approval-and-launch-of-new-pompe-disease-therapy-in-the-united-kingd
https://www.ema.europa.eu/en/documents/overview/opfolda-epar-medicine-overview_en.pdf
https://www.globenewswire.com/news-release/2023/04/26/2655517/15991/en/Amicus-Therapeutics-Receives-Positive-CHMP-Opinion-for-Opfolda-miglustat-for-Late-Onset-Pompe-Disease.html
https://www.nasdaq.com/articles/amicus-therapeutics-gets-positive-chmp-opinion-for-pombiliti
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209325
https://www.pharmaceutical-technology.com/comment/orphazymes-arimoclomol-expected-to-be-used-with-zavesca-after-likely-fda-approval-in-niemann-pick-disease-type-c/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209821
https://endpts.com/orphazyme-lead-drug-fails-both-main-goals-in-key-study-but-company-insists-the-results-are-positive/
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208342
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/veterinary/medicines/002723/vet_med_000342.jsp&mid=WC0b01ac058008d7a8
https://www.pharmacompass.com/pdf/news/Dipharma-announces-the-validation-of-disanit-nitisinone-marketing-authorization-application-in-Europe-1487846057.pdf
http://www.pharmatimes.com/news/eight_medicines_leap_towards_eu_approval_1185408
http://www.pharmatimes.com/Article/16-04-03/Seven_new_therapies_jump_towards_EU_approval.aspx
http://www.prnewswire.com/news-releases/amerigen-and-dipharma-announce-first-regulatory-submission-for-miglustat-100mg-capsules-300202534.html
http://www.prnewswire.com/news-releases/amerigen-and-dipharma-announce-first-regulatory-submission-for-miglustat-100mg-capsules-300202534.html
http://www.pmlive.com/pharma_news/sanofi_rare_disease_drug_a_breakthrough,_says_fda_750116
Market Place
Share 
